Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

Rift Valley fever vaccine ‘safe for pregnant animals’
Rift Valley fever is a virus that infects sheep, goats, cattle and camels.

Research will aid the development of ChAdOx1 RVF for human use

The Rift Valley fever (RVF) vaccine is safe for pregnant animals, according to a collaborative study led by The Pirbright Institute. 


The research, published in the journal npj Vaccines, found that pregnant sheep and goats vaccinated with a single dose of ChAdOx1 RVF remained healthy and suffered no pregnancy loss after being exposed to a virulent strain of RVF virus.

The team will use their discovery to progress the development of the vaccine, which could be the first to be used against both a human and animal disease.


“Our study has provided further evidence of the vaccine’s effectiveness and safety,” said Dr Anna Stedman, lead author of the study. “Ensuring ChAdOx1 RVF can be used in pregnant animals will help livestock owners to protect their animals in the event of an outbreak, which in turn will reduce their own risk of infection.”


Rift Valley fever is a virus that infects sheep, goats, cattle and camels. Prevalent across Africa and the Arabian Peninsula, the infection results in high mortality and poor outcomes during pregnancy. 


RVF also poses a threat to human health, but no licenced human vaccine is currently available. People can contract the disease through contaminated tissues and fluids of livestock, as well as being bitten by infected mosquitoes.


ChAdOx1 RVF was previously shown to be safe and effective at protecting animals and has since been scheduled for human trials. Until now, however, its safety in pregnant animals has not been verified. 


“This research will aid the development of ChAdOx1 RVF for human use, and for the first time we may see a vaccine that can be deployed against the same virus in both animals and humans,” said Professor Bryan Charleston, Director of The Pirbright Institute.

Professor George Warimwe, leader of the Rift Valley Fever Vaccine Programme at the University of Oxford added: “This has been a tremendous collaborative achievement. The excellent safety profile of the vaccine in pregnant livestock will support further development of the product for use in both livestock and humans.”

Become a member or log in to add this story to your CPD history

Vets launch new podcast for pet owners

News Story 1
 Two independent vets have launched a podcast to help owners strengthen their bond with pets. Dr Maggie Roberts and Dr Vanessa Howie, who have worked in both veterinary practice and major charities, are keen to use their experience to enable people to give pets a better life.

The venture, called Vets Talking Pets, provides advice and information on a range of topics, including how to select a suitable pet, where to obtain them and how to get the best out of your vet. Maggie and Vanessa will also discuss sensitive subjects, including end-of-life care, raw food diets and the cost of veterinary care.

The podcast can be found on all the usual podcast sites, including Podbean, Apple, Amazon Music and YouTube. 

Click here for more...
News Shorts
VMD issues guidance on AVM-GSL packaging

The Veterinary Medicines Directorate (VMD) has shared advice on its requirements for medicines considered AVM-GSL.

The guidance explains the information that should be on the outer package, and sets out the typical maximum pack size for an AVM-GSL product. It also describes the user-friendly language, structure and phrases required on packaging and product leaflets.

AVM-GSL products do not require discussion between the purchaser and a veterinary professional. This means that clear product information is needed to support sales choices.

The information will be useful for submitting new products to the AVM-GSL category and lowering the distribution category of products from NFA-VPS to AVM-GSL.

The VMD's guidance can be accessed here.